Skip to content Skip to footer
Subscribe Now
Viewpoints_Vijay Nadipelli
VIEWPOINTS

Evaluating SDoH in SLE: Vijay Nadipelli from GSK in a Riveting Conversation with PharmaShots

Shots:  SDoH screening can help identify patient needs, support faster clinical decisions, and improve patient-centric care  A first-of-its-kind lupus study surveyed 69 patients across two institutions to assess the feasibility of routine SDoH screening in lupus clinics and identify related barriers and enablers at the physician, care team, and patient levels  Vijay Nadipelli, Senior Director…
April 21, 2025

Read more

Viewpoints_Roger Levy
VIEWPOINTS

Evaluating SDoH in Lupus Nephritis: Roger Levy from GSK in a Stimulating Conversation with PharmaShots

Shots:  GSK presented data at the American College of Rheumatology from a multi-center cohort study highlighting the achievement of complete renal response in patients with active lupus nephritis  The study evaluated the attainment of modified complete renal response (mCRR) in patients with systemic lupus erythematosus (SLE) and active lupus nephritis (LN), comparing characteristics between mCRR…
April 2, 2025

Read more

Viewpoints_Fred Aslan
VIEWPOINTS

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots:  Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases  Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…
November 4, 2024

Read more

Disease of the Month – Systemic Lupus Erythematosus
INSIGHTS+

Disease of the Month – Systemic Lupus Erythematosus

Shots:  Systemic lupus erythematosus (SLE) is an autoimmune disorder where the body's immune system targets and damages healthy tissues  In this reprise of our Disease of the Month report, we present an enlightening description of SLE with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved    For a…
September 18, 2024

Read more

VIEWPOINTS_Micki Hultquist_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

Shots:  AstraZeneca at ACR 2023 presented 18 abstracts from its respiratory and immunology pipelines  Micki Hultquist in a stimulating conversation with PharmaShots sheds light on Saphnelo, AstraZeneca’s first-in-class biologic treatment for systemic lupus erythematosus (SLE)  The post-hoc analysis of the TULIP P-III program reveals that the patients showcased more frequent and sustained remission as compared…
February 5, 2024

Read more

Viewpoints_Priya Singhal
VIEWPOINTS

Priya Singhal, Senior Vice President at Biogen, Shares Insights from Litifilimab Systemic Lupus Erythematosus NEJM Publication

Shots: Priya spoke about the study design and key findings from the P-II (LILAC), P-III (TOPAZ-1) & (TOPAZ-2) clinical study evaluating litifilimab She also talked about the P-III trial evaluating Dapirolizumab pegol in collaboration with UCB to treat SLE The interview summarizes how Biogen’s innovative medications are helping patients with Systemic Lupus Erythematosus which has…
November 30, 2022

Read more

PharmaShots Interview GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus
VIEWPOINTS

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

In an interview with PharmaShots, Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at GSK shared her views on a first published article on disease modification in systemic lupus erythematosus, published in Lupus Science & Medicine Shots: The company has published the first research to define disease modification in SLE including LN in the Lupus Science & Medicine. In multiple therapeutic…
May 11, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]